Effective Personalized Treatment of Advanced Hepatic Carcinoma based on Sorafenib
نویسندگان
چکیده
منابع مشابه
Sorafenib in advanced hepatocellular carcinoma.
BACKGROUND No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS In this multicenter, phase 3, double-blind, placebo-control...
متن کاملSorafenib for the treatment of advanced renal cell carcinoma.
PURPOSE This report describes the U.S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for the treatment of patients with advanced renal cell carcinoma (RCC). EXPERIMENTAL DESIGN After meeting with sponsors during development studies of sorafenib, the FDA reviewed the phase 3 protocol under the Speci...
متن کاملEfficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
BACKGROUND Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC), its therapeutic benefit is marginal. Here, we aimed to compare the efficacy and safety of sorafenib monotherapy (S-M) and sorafenib-based loco-regional treatments (S-LRTs) in advanced HCC. METHODS From 2007 to 2012, 290 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C...
متن کاملSorafenib Effectiveness in Advanced Hepatocellular Carcinoma
BACKGROUND Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Because of narrow trial eligibility, results may not be generalizable to a broader HCC population. We sought to evaluate the effectiveness of initial sorafenib versus no treatment among Medicare beneficiaries with advanced HCC. MATERIALS AND METHODS Patients with advanced HCC diagnosed fro...
متن کاملNICE guidance on sorafenib for treating advanced hepatocellular carcinoma.
On Sept 6, 2017, the UK National Institute of Health and Care Excellence (NICE) published guidance that recommends sorafenib (Bayer PLC; Reading, UK), as an option for treating advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment, and only if the manufacturing company provides sorafenib within the agreed commercial access arrangement. The appraisal committe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Integrative Oncology
سال: 2016
ISSN: 2329-6771
DOI: 10.4172/2329-6771.1000164